Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lanyan Fang

Showing results (21-30 of 70) with videos related to

Pageof 7
Sort By:
Molecular Pharmaceutics|February 6, 2007
Modifying the sugar moieties of daunorubicin overcomes P-gp-mediated multidrug resistanceRobert F Battisti, Yanqiang Zhong, Lanyan Fang, et al.
Journal of Clinical Pharmacology|February 5, 2019
Is Bioequivalence Established Based on the Reference-Scaled Average Bioequivalence Approach Relevant to Chronic Administration of Phenytoin? Perspectives Based on Population Pharmacokinetic Modeling and SimulationsHyewon Kim, Lanyan Fang, Jingyu Yu, et al.
Journal of Clinical Pharmacology|May 16, 2019
Physiologically Based Pharmacokinetic Modeling to Evaluate Formulation Factors Influencing Bioequivalence of Metoprolol Extended-Release ProductsSumit Basu, Haitao Yang, Lanyan Fang, et al.
Cancer Chemotherapy and Pharmacology|August 15, 2006
Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxiaXianhua Cao, Lanyan Fang, Seth Gibbs, et al.
Journal of Medicinal Chemistry|November 15, 2008
Histone deacetylase inhibitors through click chemistryJie Shen, Robert Woodward, James Patrick Kedenburg, et al.
Clinical Pharmacology and Therapeutics|January 25, 2021
Use of Partial Area Under the Curve in Bioavailability or Bioequivalence Assessments: A Regulatory PerspectiveLanyan Fang, Ramana Uppoor, Mingjiang Xu, et al.
Pharmaceutical Research|November 6, 2025
Using Lung Regional Deposition Modeling as Model-Integrated Evidence for Locally Acting Orally Inhaled Drug ProductsRoss L Walenga, Steven G Chopski, Jae H Lee, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 1, 2022
Mechanistic modeling of drug products applied to the skin: A workshop summary reportEleftheria Tsakalozou, Khondoker Alam, Priyanka Ghosh, et al.
The AAPS Journal|April 22, 2021
Development of a Pediatric Relative Bioavailability/Bioequivalence Database and Identification of Putative Risk Factors Associated With Evaluation of Pediatric Oral ProductsGopal Pawar, Fang Wu, Liang Zhao, et al.
Journal of Pharmaceutical Sciences|October 20, 2025
Emerging perspectives on leveraging physiologically based biopharmaceutics modeling (PBBM) for BCS class III biowaivers: A webinar summaryLanyan Fang, Shereeni Veerasingham, Yunming Xu, et al.
Pageof 7

Showing results (21-30 of 70) with videos related to

Sort By:
Pageof 7
Molecular Pharmaceutics|February 6, 2007
Modifying the sugar moieties of daunorubicin overcomes P-gp-mediated multidrug resistanceRobert F Battisti, Yanqiang Zhong, Lanyan Fang, et al.
Journal of Clinical Pharmacology|February 5, 2019
Is Bioequivalence Established Based on the Reference-Scaled Average Bioequivalence Approach Relevant to Chronic Administration of Phenytoin? Perspectives Based on Population Pharmacokinetic Modeling and SimulationsHyewon Kim, Lanyan Fang, Jingyu Yu, et al.
Journal of Clinical Pharmacology|May 16, 2019
Physiologically Based Pharmacokinetic Modeling to Evaluate Formulation Factors Influencing Bioequivalence of Metoprolol Extended-Release ProductsSumit Basu, Haitao Yang, Lanyan Fang, et al.
Cancer Chemotherapy and Pharmacology|August 15, 2006
Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxiaXianhua Cao, Lanyan Fang, Seth Gibbs, et al.
Journal of Medicinal Chemistry|November 15, 2008
Histone deacetylase inhibitors through click chemistryJie Shen, Robert Woodward, James Patrick Kedenburg, et al.
Clinical Pharmacology and Therapeutics|January 25, 2021
Use of Partial Area Under the Curve in Bioavailability or Bioequivalence Assessments: A Regulatory PerspectiveLanyan Fang, Ramana Uppoor, Mingjiang Xu, et al.
Pharmaceutical Research|November 6, 2025
Using Lung Regional Deposition Modeling as Model-Integrated Evidence for Locally Acting Orally Inhaled Drug ProductsRoss L Walenga, Steven G Chopski, Jae H Lee, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 1, 2022
Mechanistic modeling of drug products applied to the skin: A workshop summary reportEleftheria Tsakalozou, Khondoker Alam, Priyanka Ghosh, et al.
The AAPS Journal|April 22, 2021
Development of a Pediatric Relative Bioavailability/Bioequivalence Database and Identification of Putative Risk Factors Associated With Evaluation of Pediatric Oral ProductsGopal Pawar, Fang Wu, Liang Zhao, et al.
Journal of Pharmaceutical Sciences|October 20, 2025
Emerging perspectives on leveraging physiologically based biopharmaceutics modeling (PBBM) for BCS class III biowaivers: A webinar summaryLanyan Fang, Shereeni Veerasingham, Yunming Xu, et al.
Pageof 7